LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

April 6, 2023

Publication of Annual Report and Accounts & Notice of AGM

06 April 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read More
March 14, 2023

Appointment of Joint Broker

14 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Appointment of Joint Broker LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect. Investec Bank plc remains Nominated Adviser and Joint Broker to the Company.  Click HERE for […]
• Read More
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down